Gilead Sciences, Inc. (GILD)
- Business Wire
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
FOSTER CITY, Calif. & ATLANTA & NEW ORLEANS, August 17, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new health equity collaboration with the Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine and the Center for Minority Health and Health Disparities Research and Education (CMHDRE) at Xavier University of Louisiana’s College of Pharmacy. The collaboration is focused on addressing the inequities in HIV care for Black communities in the Southern United State
- Zacks
Gilead (GILD) Announces Positive Data on Breast Cancer Drug
Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.
- Business Wire
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
FOSTER CITY, Calif., August 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.
